



New connection on: : 27-07-2018 : 19:09:34 - Last disconnection on: : 25-07-2018 : 23:01:17

V 4.0.0.44358(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201802)) (RPM D201802)

Welcome to EPOQUE Rebuild under the Production Environment

[No database/cluster active] ..fi epodoc



Database: EPODOC

[EPODOC: SS 1] Folding and rigid and stretcher

Results in EPODOC 48

[SS 2] ss1 and sensor

Results in EPODOC 134

[SS 3] ss2 and (vital w signs)

Results in EPODOC 0

[SS 4] ss2

Results in EPODOC 1.189

[SS 5] ss1 and sensor

Results in EPODOC 134

[SS 6] ss5 and treatment

Results in EPODOC 5

[SS 7] ..li



1/5 © EPODOC / EPO

WPT02018020101

PN - [CA2958906](#) A1 20160225

PR - US201462040503P
20140822; WO2015US46322
20150821

AP - CA20152958906 20150821

DT - I

CCI - [C12N9/6418](#)


CUI - [C07K14/46](#)

CCA - [A61K38/00](#)

PA - UNIV NAT CHENG KUNG [TW];
DCB-USA LLC [US]

TI - DISINTEGRIN VARIANTS AND
PHARMACEUTICAL USES THEREOF

AB - Disintegrin variants that bind
specifically to one or more of
 $\alpha 5\beta 1$ and αv integrins, such as $\alpha ?$
 $\beta 1$, $\alpha ?\beta 3$, $\alpha ?\beta 5$, $\alpha ?\beta 6$ and $\alpha ?\beta 8$,
but with reduced binding activity
to $\alpha 1\beta 3$, are described. Also
described are uses of the
disintegrin variants for
the **treatment** or prevention of a
disease associated with an αv
integrin or an $\alpha 5\beta 1$ integrin.



2/5 © EPODOC / EPO

PN - [CN106263012](#) A 20170104

PNFP - CN106263012B B 20170915


PR - CN20161807097 20160906

AP - CN20161807097 20160906

DT - I

CT - || STSE (A)
[CN105142429](#) A 20151209
[A] (PHILIP MORRIS PRODUCTS
SA)
[A] 1—10
* 全文 *;
[CN105595399](#) A 20160525
[X] (CHINA TOBACCO JIANGSU
IND CO)
[X] 1—10
* 权利要求1-9 *

CNOI - (A)
[A24B3/04](#) ; [A24B3/12](#) ;
[A24B15/22](#) ; [A24B15/24](#)



PA	- (A) CHINA TOBACCO JIANGSU IND CO
TI	- (A) Tobacco raw material treatment method for low temperature cigarettes
AB	- (A) The invention discloses a tobacco raw material treatment method for low temperature cigarettes. The method comprises the following steps: step SS1, adding alkali liquor in tobacco raw materials for extraction, carrying out ultrasonic treatment , and executing the step SS2; step SS2, filtering for removing the extraction alkali liquor in the step SS1, adding pure water to quickly wash the tobacco raw materials, discarding the washing liquid, and executing the step SS3; step SS3, drying the tobacco raw materials prepared in the step SS2 at a low temperature, and executing the step SS4; step SS4, putting the tobacco raw materials dried in the step SS3 in a balanced environment for 24-48h, spraying an absolute ethyl alcohol solution containing tobacco essence and polyhydric alcohol to the tobacco raw materials, putting the tobacco raw materials in a sealed state for 24-48h, and executing the step SS5 ; and step SS5 , putting the tobacco raw materials prepared in the step SS4 in the balanced environment for 48h to obtain tobacco materials suitable for heating non- combustion cigarettes. The smoke released by the tobacco raw materials treated by the method disclosed by the invention in a heating non-

combustion state is large in concentration, mild and soft, small in irritation and moderate in intensity.

3/5 © EPODOC / EPO

PN - [CA2903546](#) A1 20140925

PR - US201361792681P
20130315; US201361898811P
20131101; WO2014US26234
20140313

AP - CA20142903546 20140313

DT - I

CCI - [A61K39/3955](#) ; [C07K16/2839](#)


CUI - [A61K45/06](#)

CUA - [A61K2039/505](#) ; [C07K2317/24](#)

PA - BIOGEN MA INC [US]

TI - **TREATMENT** AND PREVENTION OF ACUTE KIDNEY INJURY USING ANTI-ALPHA V BETA 5 ANTIBODIES

AB - Methods of using antibodies and antibody fragments that specifically bind avss5 or ss5 to treat or prevent acute kidney injury and/or its sequelae are disclosed.



4/5 © EPODOC / EPO

PN - [RU2165455](#) C1 20010420

PR - RU19990124276 19991123

AP - RU19990124276 19991123

DT - I

PA - GNIN INST [RU]; OSOBO CHISTYKH BIOPREPARATOV [RU]; OIZVODSTVENNAJA KOMPANIJA DIAP [UA]; N PR AOZT [UA]; SOJUZAGROMED AOZT [RU]; G NTS PRIKLADNOJ MIKROBIOLOGII [RU]

TI - RECOMBINANT PLASMID DNA PSS5 ENCODING SYNTHESIS OF RECOMBINANT HUMAN ALPHA-2B INTERFERON, STRAIN OF ESCHERICHIA COLI **SS5** AS PRODUCER OF RECOMBINANT HUMAN ALPHA-2B INTERFERON AND METHOD OF ALPHA-2B INTERFERON PREPARING

AB - biotechnology, molecular biology, genetic engineering. SUBSTANCE: cells of recipient strain E. coli BL 21 (DE3) is transformed by recombinant multicopy plasmid DNA pSS5 encoding synthesis of leukocyte human alpha-2b interferon. Expression of the latter is under control of lactose gene, phage T7 and tryptophan promoters and terminator of translation rrn B-T1T2 containing gene determining the resistance to kanamycin and containing DNA fragment from plasmid pUC19 that is responsible for replication of

recombinant plasmid. Obtained strain E. coli **SS5** has productivity 800 mg of alpha-2b interferon, not less, with total activity 1-2 x 10¹¹ IU/1 l of cultural medium or 15-20 g of wet biomass of strain cells. Method involves culturing on nutrient medium, freezing cultural liquid at -70 C, not above, its defrosting by temperature increase to 4 C followed by addition of lysozyme to cultural liquid, removal of DNA and RNA by **treatment** of lyzate with DNase, concentration of obtained product by protein washing off with solutions of nonionic detergents, centrifugation and dissolving formed precipitate in solution of guanidine hydrochloride followed by renaturation of interferon and its purification using ion-exchange chromatography on ion-exchange resins of type Whatman CM-52-cellulose. Invention can be used for preparing recombinant human leukocyte alpha-2b interferon for medicinal aims. EFFECT: increased yield of interferon producing. 7 cl, 4 dwg, 3 ex

5/5 © EPODOC / EPO

PN - [KR20080037426](#) A 20080430

PNFP - KR101238009B B1 20130304

PR - KR20060104574 20061026

AP - KR20060104574 20061026

DT - I

CT - || STSE (B1)
[JP2004199088](#) A 20040715 [] (DAINIPPON PRINTING CO LTD);
[KR20050041464](#) A 20050504 [] (SAMSUNG ELECTRONICS CO LTD [KR]);
[KR20050012480](#) A 20050202 [] (SAMSUNG CORNING CO LTD);
[KR100521258B](#) B1 20051006 [] (SAMSUNG ELECTRONICS CO LTD [KR])

CNOI - (A)
[G02F1/133305](#) ; [G02F1/133382](#)

CNOA - (A)
[G02F2202/02](#)

PA - (A)
 LG DISPLAY CO LTD [KR]

TI - (A)
 FABRICATING METHOD OF FLEXIBLE DISPLAY

- (B1)
 Fabricating Method of Flexible Display

AB - (A)
 A method of manufacturing a flexible display device is provided to stabilize a drive characteristic of TFT and enhance the reliability of TFT by separating a flexible substrate with TFT from an adhesive agent and a support substrate and then performing a heat **treatment** . A method of manufacturing a flexible display device includes several processes; adhering between a flexible substrate and a nonflexible support substrate by using adhesive agent(SS1); forming thin film patterns on the flexible substrate(SS3); separating the adhesive agent and the support substrate from the flexible substrate (SS5); and performing a heat **treatment** for the flexible substrate and the thin film patterns(SS7).